
Douglas Johnson, M.D., M.S.C.I.
- Susan and Luke Simons Directorship
- Co-Leader, Translational Research and Interventional Oncology Research Program
- Associate Professor of Medicine (Hematology/Oncology)
- Clinical Director, Melanoma
Phone
2220 Pierce Avenue
Nashville, TN 37232
Douglas Johnson, M.D., M.S.C.I.
- Susan and Luke Simons Directorship
- Co-Leader, Translational Research and Interventional Oncology Research Program
- Associate Professor of Medicine (Hematology/Oncology)
- Clinical Director, Melanoma
615-936-3524
douglas.b.johnson@vumc.org
2220 Pierce Avenue
Nashville, TN 37232
Research Program
Departments/Affiliations
Provider Information
Profile
Dr. Johnson is a medical oncologist specializing in melanoma skin cancer. After receiving his MD from University of Alabama at Birmingham, he completed residency at Duke University followed by fellowship at Vanderbilt. He is also a graduate of the Master of Science in Clinical Investigation Program at Vanderbilt.
Dr. Johnson leads the melanoma clinical research program at Vanderbilt. His research interests cover a wide range of developing new immune and targeted therapies for melanoma, and in using existing treatments in the most effective ways. Specifically, he is exploring ways to profile cancers to predict which patients will benefit from immune therapies, and has published numerous papers in this area. He is also focused on understanding the effectiveness and toxicities of immune therapies in high risk patients, including those with autoimmune disorders, advanced age, or organ dysfunction. Dr. Johnson is the lead investigator on numerous clinical trials at Vanderbilt.
Education
- M.D., University of Alabama at Birmingham
- Residency, Duke University
- Fellowship, Vanderbilt University
- M.S.C.I., Vanderbilt University
Research Emphasis
Research Description
Publications
- Johnson DB, Bordeaux JM, Kim JY, Vaupel CA, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy JW, Witte JS, McKee SB, Ko J, Wrangle J, Dabbas B, Tangri S, Lameh J, Hall JM, Markowitz J, Balko JM, Dakappagari NK. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma. Clin. Cancer Res [print-electronic]. 2018 Jul 7/18/2018; PMID: 30021908, PII: 1078-0432.CCR-18-0309, DOI: 10.1158/1078-0432.CCR-18-0309, ISSN: 1078-0432.
- Johnson DB. Toxicities and outcomes: Do steroids matter? [editorial]. Cancer [print-electronic]. 2018 Jul 7/5/2018; PMID: 29975416, DOI: 10.1002/cncr.31627, ISSN: 1097-0142.
- Johnson DB, Daniels AB. Continued Poor Survival in Metastatic Uveal Melanoma: Implications for Molecular Prognostication, Surveillance Imaging, Adjuvant Therapy, and Clinical Trials. JAMA Ophthalmol [print-electronic]. 2018 Jun 6/28/2018; PMID: 29955760, PII: 2686114, DOI: 10.1001/jamaophthalmol.2018.1813, ISSN: 2168-6173.
- Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin. Cancer Res [print-electronic]. 2018 Jun 6/13/2018; PMID: 29898988, PII: 1078-0432.CCR-18-1116, DOI: 10.1158/1078-0432.CCR-18-1116, ISSN: 1078-0432.
- Davis EJ, Johnson DB, Sosman JA, Chandra S. Melanoma: What do all the mutations mean?. Cancer [print-electronic]. 2018 Apr 4/17/2018; PMID: 29663336, DOI: 10.1002/cncr.31345, ISSN: 1097-0142.
- Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis [letter]. Lancet. 2018 Mar 3/10/2018; 391(10124): 933. PMID: 29536852, PII: S0140-6736(18)30533-6, DOI: 10.1016/S0140-6736(18)30533-6, ISSN: 1474-547X.
- McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol [print-electronic]. 2018 Mar; 19(3): 310-22. PMID: 29449192, PMCID: PMC5840029, PII: S1470-2045(18)30078-0, DOI: 10.1016/S1470-2045(18)30078-0, ISSN: 1474-5488.
- Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A. High response rate to PD-1 blockade in desmoplastic melanomas. Nature [print-electronic]. 2018 Jan 1/18/2018; 553(7688): 347-50. PMID: 29320474, PMCID: PMC5773412, PII: nature25187, DOI: 10.1038/nature25187, ISSN: 1476-4687.
- Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB, Balko JM. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018; 7(6): e1438106. PMID: 29872580, PMCID: PMC5975601, PII: 1438106, DOI: 10.1080/2162402X.2018.1438106, ISSN: 2162-4011.
- Wang DY, Johnson DB, Davis EJ. Toxicities Associated With PD-1/PD-L1 Blockade. Cancer J. 2017 Dec; 24(1): 36-40. PMID: 29360726, PMCID: PMC5784852, PII: 00130404-201801000-00007, DOI: 10.1097/PPO.0000000000000296, ISSN: 1540-336X.